Recombinant factor VIIa in joint and muscle bleeding episodes.
Recombinant factor VIIa (rFVIIa) improves haemostasis and eliminates the risk of transmission of blood-borne infection in haemophilia patients with inhibitors, acquired inhibitors to factor VIII or IX or FVII deficiency. rFVIIa has been available on a compassionate use basis since 1988 and has been administered to 111 patients for a total of 494 joint and muscle bleeding episodes. Seventy-nine percent of joint and 65% of muscle bleeding episodes were evaluated by the investigator as having an excellent/effective response. rFVIIa is also an effective treatment for joint and muscle bleeding episodes in patients undergoing immune tolerance regimens and does not affect the inhibitor titre level.
Bech
R M
RM
Novo Nordisk, Gentofte, Denmark.
D015942:Factor VIIa / Q000009:adverse effects / Q000627:therapeutic use*; D006467:Hemophilia A / Q000150:complications / Q000188:drug therapy*; D006470:Hemorrhage / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007592:Joint Diseases / Q000188:drug therapy* / Q000209:etiology; D009135:Muscular Diseases / Q000188:drug therapy* / Q000209:etiology; D018579:Patient Selection; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012189:Retrospective Studies; D016896:Treatment Outcome
D011994:Recombinant Proteins; D015942:Factor VIIa